nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное общество10.28996/2618-9801-2024-2suppl-70-113nid-362Research ArticleСтатьиПроект инициативных клинических рекомендаций по диагностике и лечению волчаночного нефритаClinical recommendations on diagnostics and treatment of lupus nephritis (draft project)https://orcid.org/0000-0003-0178-7549ЗахароваЕ. В.ZakharovaE. V.

Захарова Елена Викторовна – к.м.н., заведующая нефрологическим отделением №24, старший научный сотрудник, ГБУЗ ММНКЦ Боткинская больница ДЗМ; доцент кафедры нефрологии и гемодиализа ФГБОУ ДПО РМАНПО МЗ РФ; доцент кафедры нефрологии лечебного факультета Научно-образовательного института клинической медицины им. Н.А. Семашко ФГБОУ ВО «Российский университет медицины» МЗ РФ

125284, Россия, Москва, 2-й Боткинский проезд, 5125993, Москва, ул. Баррикадная, 2/1, стр. 1127006, Москва, ул. Долгоруковская, 4

Zakharova Elena Viktorovna

5, 2nd Botkinsky drive, 125284, Moscow2/1, bld 1, Barrikadnaya str., 125993, Moscow4, Dolgorukovskaya str., 127006, Moscow

helena.zakharova@gmail.comhttps://orcid.org/0000-0002-4275-0315КозловскаяН. Л.KozlovskayaN. L.

Козловская Наталья Львовна – д-р мед. наук, профессор, руководитель центра помощи беременным с патологией почек и мочевыводящих путей, ГБУЗ ГКБ им. А.К. Ерамишанцева ДЗМ; профессор кафедры внутренних болезней с курсами кардиологии и функциональной диагностики им. академика В.С. Моисеева РУДН

129327, Москва, ул. Ленская, 15117198, Москва, ул. Миклухо-Маклая, 6

Kozlovskaya Natalia Lvovna

15, Lenskaya str., 129327, Moscow6, Mikluho-Maklaya str., 117198, Moscow

nkozlovskaya@yandex.ruhttps://orcid.org/0000-0002-0880-6346КоротчаеваЮ. В.KorotchaevaY. V.

Коротчаева Юлия Вячеславовна – д-р мед. наук, доцент кафедры внутренних, профессиональных болезней и ревматологии Института клинической медицины, ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет) Министерства здравоохранения Российской Федерации, врач-нефролог центра помощи беременным с патологией почек и мочевыводящих путей, ГБУЗ «ГКБ им. А.К. Ерамишанцева» Департамента здравоохранения г. Москвы, Москва,

129327, Москва, ул. Ленская, 15119048, Москва, ул. Трубецкая, 8, стр. 2

Korotchaeva Yulia Vyacheslavovna

15, Lenskaya str., 129327, Moscow, Russian Federation8, bld 2, Trubetskaya str., 119048

lumis-j@bk.ruhttps://orcid.org/0000-0002-8007-5680БобковаИ. Н.BobkovaI. N.

Бобкова Ирина Николаевна – д-р мед. наук, профессор кафедры внутренних, профессиональных болезней и ревматологии, ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет) Министерства здравоохранения Российской Федерации

119048, Москва, ул. Трубецкая, 8, стр. 2

Bobkova Irina Nikolaevna

8, bld 2, Trubetskaya str., 119048

irbo.mma@mail.ruhttps://orcid.org/0000-0002-7179-5520ДобронравовВ. А.DobronravovV. A.

Добронравов Владимир Александрович – д-р мед. наук, директор Научно-исследовательского института нефрологии по научной работе, профессор кафедры пропедевтики внутренних болезней с клиникой, «Первый Санкт-Петербургский государственный медицинский университета им. акад. И.П. Павлова»

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Dobronravov Vladimir Alexandrovich

6-8, Lev Tolstoy str., 197022, Saint Petersburg

dobronravov@nephrolog.ruhttps://orcid.org/0000-0003-0758-8137КаруннаяА. В.KarunnayaA. V.

Карунная Анна Викторовна – врач-нефролог отделения хронического гемодиализа клиники Научно-исследовательского института нефрологии, ассистент кафедры пропедевтики внутренних болезней с клиникой, «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова»

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Karunnaya Anna Viktorovna

6-8, Lev Tolstoy str., 197022, Saint Petersburg

a.v.karunnaya@yandex.ruГБУЗ ММНКЦ «Боткинская больница» ДЗМ; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГБОУ ВО «Российский университет медицины» МЗ РФРоссияMoscow Scientific Clinical Center “Botkin Hospital”; Russian Medical Academy of Continuing Professional Education; Russian University of MedicineRussian FederationГБУЗ «ГКБ им. А.К. Ерамишанцева» ДЗМ; ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»РоссияA.K. Eramishantsev City Hospital; RUDN UniversityRussian FederationГБУЗ «ГКБ им. А.К. Ерамишанцева» ДЗМ; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияA.K. Eramishantsev City Hospital; Sechenov UniversityRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияSechenov UniversityRussian FederationФГБОУ ВО «Первый СПб ГМУ им. акад. И.П. Павлова» Минздрава РоссииРоссияPavlov First Saint Petersburg State Medical UniversityRussian Federation202413082024262Приложение70113Copyright © Захарова Е.В., Козловская Н.Л., Коротчаева Ю.В., Бобкова И.Н., Добронравов В.А., Карунная А.В., 20242024Захарова Е.В., Козловская Н.Л., Коротчаева Ю.В., Бобкова И.Н., Добронравов В.А., Карунная А.В.Zakharova E.V., Kozlovskaya N.L., Korotchaeva Y.V., Bobkova I.N., Dobronravov V.A., Karunnaya A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/362

.

ReferencesRahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939. DOI: 10.1056/NEJMra071297Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939. DOI: 10.1056/NEJMra071297Tsokos G.C. Systemic lupus erythematosus. N Engl J Med. 2011. 365(22):2110-2121. doi: 10.1056/NEJMra1100359Tsokos G.C. Systemic lupus erythematosus. N Engl J Med. 2011. 365(22):2110-2121. doi: 10.1056/NEJMra1100359Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. DOI: 10.1111/j.1523-1755.2004.00443.xWeening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. DOI: 10.1111/j.1523-1755.2004.00443.xRovin BH, Caster DJ, Cattran DC et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int. 2019;95(2):281-295. DOI: 10.1016/j.kint.2018.11.008Rovin BH, Caster DJ, Cattran DC et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int. 2019;95(2):281-295. DOI: 10.1016/j.kint.2018.11.008Rekvig OP, van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014;36:301-311. DOI: 10.1007/s00281-014-0428-6Rekvig OP, van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014;36:301-311. DOI: 10.1007/s00281-014-0428-6Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329-341. DOI: 10.1038/nrneph.2015.33Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329-341. DOI: 10.1038/nrneph.2015.33Attar SM, Koshak EA. Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid. Saudi Med J. 2010;31(7):781-787.Attar SM, Koshak EA. Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid. Saudi Med J. 2010;31(7):781-787.Sengupta M, Morel L. Lupus at the molecular level. Protein Cell. 2011;2(12):941-943. DOI: 10.1007/s13238-011-1123-1Sengupta M, Morel L. Lupus at the molecular level. Protein Cell. 2011;2(12):941-943. DOI: 10.1007/s13238-011-1123-1Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-318. DOI: 10.1191/0961203306lu2305xxDanchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-318. DOI: 10.1191/0961203306lu2305xxAringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2019;71(9):1400-1412. DOI: 10.1002/art.40930Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2019;71(9):1400-1412. DOI: 10.1002/art.40930Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630-640. DOI: 10.1002/art.1780350606Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630-640. DOI: 10.1002/art.1780350606Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-2558. DOI: 10.1056/NEJMoa051135Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-2558. DOI: 10.1056/NEJMoa051135Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. DOI: 10.1016/j.kint.2017.11.023Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. DOI: 10.1016/j.kint.2017.11.023Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9(11):687-694. DOI: 10.1038/nrrheum.2013.103Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9(11):687-694. DOI: 10.1038/nrrheum.2013.103Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. DOI: 10.2215/CJN.05780616.Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. DOI: 10.2215/CJN.05780616.Schwartz MM, Korbet SM, Lewis EJ et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23(4):1298-1306. DOI: 10.1093/ndt/gfm775Schwartz MM, Korbet SM, Lewis EJ et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23(4):1298-1306. DOI: 10.1093/ndt/gfm775Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23(1):149-154. DOI: 10.1681/ASN.2011060558Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23(1):149-154. DOI: 10.1681/ASN.2011060558Dube GK, Markowitz GS, Radhakrishnan J et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. DOI: 10.5414/cnp57120Dube GK, Markowitz GS, Radhakrishnan J et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. DOI: 10.5414/cnp57120Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. DOI: 10.1681/ASN.2004050350Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. DOI: 10.1681/ASN.2004050350Hernandez-Molina G, Garcia-Trejo LP, Uribe N et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503-508.Hernandez-Molina G, Garcia-Trejo LP, Uribe N et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503-508.Wu LH, Yu F, Tan Y et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715-723. DOI: 10.1038/ki.2012.409Wu LH, Yu F, Tan Y et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715-723. DOI: 10.1038/ki.2012.409Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf.Chronic Kidney Disease (CKD). Clinical Recommendations. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf. (In Russian)Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., Suppl. 2013;3:1-150. DOI: 10.1038/kisup.2012.73Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., Suppl. 2013;3:1-150. DOI: 10.1038/kisup.2012.73Камышова ЕС. Клинические практические рекомендации KDIGO 2012 по диагностике и лечению Хронической болезни почек (перевод на русский язык под ред. Е.В. Захаровой). Нефрология и диализ. 2017;19(1):23-206.Kamyshova ES. KDIGO 2012 Clinicheskie practicheskie recomendatsii po diagnostike i lecheniyu chroniceskoy bolesni pochek (Translation into Russian, ed by EV Zakharova). Nephrology and Dialysis. 2017;19(1):23-206. (In Russian)Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. DOI: 10.1016/j.kint.2023.10.018Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. DOI: 10.1016/j.kint.2023.10.018Mosca M, Costenbader KH, Johnson SR et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol. 2019;71(1):91-98. DOI: 10.1002/art.40674Mosca M, Costenbader KH, Johnson SR et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol. 2019;71(1):91-98. DOI: 10.1002/art.40674Leuchten N, Milke B, Winkler-Rohlfing B et al. Early symptoms of systemic lupus erythematosus (SLE) re-called by 339 SLE patients. Lupus. 2018;27(9):1431-1436. DOI: 10.1177/0961203318776093Leuchten N, Milke B, Winkler-Rohlfing B et al. Early symptoms of systemic lupus erythematosus (SLE) re-called by 339 SLE patients. Lupus. 2018;27(9):1431-1436. DOI: 10.1177/0961203318776093Козловская Н.Л., Захарова Е.В. Системная красная волчанка в книге Нефрология. Национальное руководство, краткое издание. Издательство «ГЭОТАР-Медиа». 2014. С.269-287. ISBN: 987-5-9704-3014-9Kozlovskaya NL, Zakharova EV. Systemnaya krasnaya volchanka v knige Nefrologia. Natsionalnoe rukovodstvo, kratkoe izdanie. Publisher “GEOTAR-Media” 2014. P.269-287 ISBN: 987-5-9704-3014-9 (In Russian)Barbhaiya M, Zuily S, Naden R et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. DOI: 10.1136/ard-2023-224609Barbhaiya M, Zuily S, Naden R et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. DOI: 10.1136/ard-2023-224609Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2005;14(1):25-30. DOI: 10.1191/0961203305lu2055oaBalow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2005;14(1):25-30. DOI: 10.1191/0961203305lu2055oaCorapi KM, Dooley MA, Pendergraft WF 3rd. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015;17(1):110. DOI: 10.1186/s13075-015-0621-6Corapi KM, Dooley MA, Pendergraft WF 3rd. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015;17(1):110. DOI: 10.1186/s13075-015-0621-6Dall’Era M, Cisternas MG, Smilek DE et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-1313. DOI: 10.1002/art.39026Dall’Era M, Cisternas MG, Smilek DE et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-1313. DOI: 10.1002/art.39026Ugolini-Lopes MR, Seguro LPC, Castro MXF et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med. 2017;4(1):e000213. DOI: 10.1136/lupus-2017-000213Ugolini-Lopes MR, Seguro LPC, Castro MXF et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med. 2017;4(1):e000213. DOI: 10.1136/lupus-2017-000213Tamirou F, Lauwerys BR, Dall'Era M et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. DOI: 10.1136/lupus-2015-000123.Tamirou F, Lauwerys BR, Dall'Era M et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. DOI: 10.1136/lupus-2015-000123.Wang S, Spielman A, Ginsberg M et al. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. Clin J Am Soc Nephrol. 2022;17(8):1150-1158. DOI: 10.2215/CJN.01280122Wang S, Spielman A, Ginsberg M et al. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. Clin J Am Soc Nephrol. 2022;17(8):1150-1158. DOI: 10.2215/CJN.01280122Konieczny A, Kasenberg I, Mikołajczak A et al. Baseline Proteinuria and Serum Creatinine Concentration as Clinical Predictors of Complete Renal Response in Patients with Lupus Nephritis: A Single-Center Experience. Int J of Environ Res Public Health. 2022;19(23):15909. DOI: 10.3390/ijerph192315909Konieczny A, Kasenberg I, Mikołajczak A et al. Baseline Proteinuria and Serum Creatinine Concentration as Clinical Predictors of Complete Renal Response in Patients with Lupus Nephritis: A Single-Center Experience. Int J of Environ Res Public Health. 2022;19(23):15909. DOI: 10.3390/ijerph192315909Sayer J, McCarthy MP, Schmidt JD. Identification and significance of dysmorphic versus isomorphic hematuria. J Urol. 1990;143(3):545-548. DOI: 10.1016/s0022-5347(17)40015-2Sayer J, McCarthy MP, Schmidt JD. Identification and significance of dysmorphic versus isomorphic hematuria. J Urol. 1990;143(3):545-548. DOI: 10.1016/s0022-5347(17)40015-2Rahman P, Gladman DD, Ibanez D et al. Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus. 2001;10(6):418-423. DOI: 10.1191/096120301678646164Rahman P, Gladman DD, Ibanez D et al. Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus. 2001;10(6):418-423. DOI: 10.1191/096120301678646164Ding JYC, Ibanez D, Gladman D, Urowitz MB. Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. J Rheumatol. 2015;42(3):437-440. DOI: 10.3899/jrheum.140415Ding JYC, Ibanez D, Gladman D, Urowitz MB. Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. J Rheumatol. 2015;42(3):437-440. DOI: 10.3899/jrheum.140415Korbet SM, Whittier WL, Lewis EJ. The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis. Nephron Extra. 2016;6(2):12-21. DOI: 10.1159/000448487Korbet SM, Whittier WL, Lewis EJ. The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis. Nephron Extra. 2016;6(2):12-21. DOI: 10.1159/000448487Almaani S, Bhatt U, Arriens C. Creatinine Fluctuation in Patients with Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney Int Rep. 2020;5(8):1302-1305. DOI:10.1016/j.ekir.2020.05.011Almaani S, Bhatt U, Arriens C. Creatinine Fluctuation in Patients with Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney Int Rep. 2020;5(8):1302-1305. DOI:10.1016/j.ekir.2020.05.011Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021Бобкова ИН, Буланов НМ, Захарова ЕВ и соавт. Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней (перевод на русский язык под ред. Е.В. Захаровой). Нефрология и диализ. 2022;24(4):577-874. DOI: 10.28996/2618-9801-2022-4-577-874Bobkova IN, Bulanov NM, Zakharova EV et al. KDIGO 2021 Clinicheskie practicheskie recomendatsii po lecheniyu glomeruljarnykh bolesney (Translation into Russian ed by EV Zakharova). Nephrology and Dialysis. 2022;24(4):577-874. (In Russian). DOI: 10.28996/2618-9801-2022-4-577-874Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1-S69. DOI: 10.1016/j.kint.2023.09.002Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1-S69. DOI: 10.1016/j.kint.2023.09.002Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol. 2013;40(5):630-633. DOI: 10.3899/jrheum.121094Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol. 2013;40(5):630-633. DOI: 10.3899/jrheum.121094Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940Захарова ЕВ. Совместные рекомендации Евро­пейской лиги по борьбе с ревматизмом и Европейской почечной ассоциации-Европейской ассоциации диализа и трансплантации по ведению волчаночного нефрита у взрослых и детей (перевод на русский язык). Нефрология и диализ. 2012;14(4):206-222.Zakharova EV. Sovmestnye recomendatsii Evropeyskoy ligi po borbe s revmatismom y Evropeyskoy pochechnoy assaciacii-Evropeyskot associacii dyalisa y transplantacii po vedeniyu volchanochnogo nefrita u vsroslyh y detey (Translation into Russian). Nephrology and Dialysis. 2012;14(4):206-222. (In Russian)Козловская НЛ, Моисеев СВ, Новиков ПИ. Лечение волчаночного нефрита: новые рекомендации EULAR/ERA-EDTA. Клиническая фармакология и терапия. 2013;22(1):62-68.Kozlovskaya NL, Moiseev SV, Novikov PI. Lechenie volchanochnogo nefrita: novie recomendatsii EULAR/ERA-EDTA. Kliniceskaya pharmakologia y terapia. 2013;22(1):62-68. (In Russian)Козловская НЛ, Захарова ЕВ, Коротчаева ЮВ. Гломерулонефрит при системной красной волчанке в книге Национальные клинические рекомендации по лечению гломерулонефритов. Издательство «Белый Ветер». 2015.С.177-200.Kozlovskaya NL, Zakharova EV, Korotchaeva YV. Glomerulonefrit pri systemnoy krasnoy volchanke v knige Natsionalnye klinicheskie recomendatsii po lechenyu glomerulonefritov. Publisher “Belyj Veter”. 2015.P.177-200. (in Russian)Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924Козловская НЛ, Соловьев СК, Асеева ЕА и соавт. Обновленные рекомендации EULAR/ERA–EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов. Часть I. Современная ревматология. 2020;14(4):7-15.Kozlovskaya NL, Solovyev SK, Aseeva E.A et al. The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(4):7-15. (In Russ.) DOI: 10.14412/1996-7012-2020-4-7-15Jeong S, Yang D, Lee W et al. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(2):334-342. DOI: 10.1016/j.semarthrit.2018.01.011Jeong S, Yang D, Lee W et al. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(2):334-342. DOI: 10.1016/j.semarthrit.2018.01.011Birmingham DJ, Irshaid F, Nagaraja HN et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272-1280. DOI: 10.1177/0961203310371154Birmingham DJ, Irshaid F, Nagaraja HN et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272-1280. DOI: 10.1177/0961203310371154Yang XW, Tan Y, Yu F et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant. 2012;27(9):3552-3559. DOI: 10.1093/ndt/gfs179Yang XW, Tan Y, Yu F et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant. 2012;27(9):3552-3559. DOI: 10.1093/ndt/gfs179Stanley JH, Cornella R, Loevinger E et al. Sonography of systemic lupus nephritis. Am J Roentgenology. 1984;142(6):1165-1168. DOI: 10.2214/ajr.142.6.1165.Stanley JH, Cornella R, Loevinger E et al. Sonography of systemic lupus nephritis. Am J Roentgenology. 1984;142(6):1165-1168. DOI: 10.2214/ajr.142.6.1165.Longmaid HE 3rd, Rider E, Tymkiw J. Lupus nephritis. New sonographic findings. J Ultrasound Med. 1987;6(2):75-79. DOI: 10.7863/jum.1987.6.2.75Longmaid HE 3rd, Rider E, Tymkiw J. Lupus nephritis. New sonographic findings. J Ultrasound Med. 1987;6(2):75-79. DOI: 10.7863/jum.1987.6.2.75Thurman JM, Serkova NJ. Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research. 2015;4:153. DOI: 10.12688/f1000research.6587.2Thurman JM, Serkova NJ. Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research. 2015;4:153. DOI: 10.12688/f1000research.6587.2Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part II: gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68(2):192-202. DOI: 10.1016/j.crad.2012.06.109.Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part II: gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68(2):192-202. DOI: 10.1016/j.crad.2012.06.109.Conti F, Ceccarelli F, Gigante A et al. Ultrasonographic Evaluation of Renal Resistive Index in Patients with Lupus Nephritis: Correlation with Histologic Findings. Ultrasound in Med Biol. 2014;40(11):2573-2580. DOI: 10.1016/j.ultrasmedbio.2014.06.016Conti F, Ceccarelli F, Gigante A et al. Ultrasonographic Evaluation of Renal Resistive Index in Patients with Lupus Nephritis: Correlation with Histologic Findings. Ultrasound in Med Biol. 2014;40(11):2573-2580. DOI: 10.1016/j.ultrasmedbio.2014.06.016Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS) – APS nephropathy. Clin Rev Allergy Immunol. 2009;36(2-3):131-140. DOI: 10.1007/s12016-008-8112-zTektonidou MG. Renal involvement in the antiphospholipid syndrome (APS) – APS nephropathy. Clin Rev Allergy Immunol. 2009;36(2-3):131-140. DOI: 10.1007/s12016-008-8112-zLalani TA, Kanne JP, Hatfield GA, Chen P. Imaging findings in systemic lupus erythematosus. Radiographics. 2004;24(4):1069-1086. DOI: 10.1148/rg.244985082Lalani TA, Kanne JP, Hatfield GA, Chen P. Imaging findings in systemic lupus erythematosus. Radiographics. 2004;24(4):1069-1086. DOI: 10.1148/rg.244985082Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part I: CNS, cardiovascular, and thoracic manifestations. Clin Radiol. 2013;68(2):181-191. DOI: 10.1016/j.crad.2012.06.110Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part I: CNS, cardiovascular, and thoracic manifestations. Clin Radiol. 2013;68(2):181-191. DOI: 10.1016/j.crad.2012.06.110van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. DOI: 10.1136/annrheumdis-2013-205139van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. DOI: 10.1136/annrheumdis-2013-205139Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years. Kidney Int. 2007;71(6):491-495. DOI: 10.1038/sj.ki.5002118Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years. Kidney Int. 2007;71(6):491-495. DOI: 10.1038/sj.ki.5002118Rijnink EC, Teng YKO, Kraaij T et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int. 2018;93(1):214-220. DOI: 10.1016/j.kint.2017.07.017Rijnink EC, Teng YKO, Kraaij T et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int. 2018;93(1):214-220. DOI: 10.1016/j.kint.2017.07.017Wang H, Ren YL, Chang J et al. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol. 2017;33(1):17-25. DOI: 10.5606/ArchRheumatol.2017.6127Wang H, Ren YL, Chang J et al. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol. 2017;33(1):17-25. DOI: 10.5606/ArchRheumatol.2017.6127Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089van Vollenhoven R, Voskuyl A, Bertsias G et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-561. DOI: 10.1136/annrheumdis-2016-209519van Vollenhoven R, Voskuyl A, Bertsias G et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-561. DOI: 10.1136/annrheumdis-2016-209519Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther. 2012;14:202. DOI: 10.1186/ar3656Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther. 2012;14:202. DOI: 10.1186/ar3656Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28. DOI: 10.1136/ard.2008.101766Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28. DOI: 10.1136/ard.2008.101766Pakchotanon R, Gladman DD, Su J, Urowitz MB. More Consistent Antimalarial Intake in First 5 Years of Disease is Associated with Better Prognosis in Patients with Systemic Lupus Erythematous. J Rheumatol. 2018;45(1):90-94. DOI: 10.3899/jrheum.170645Pakchotanon R, Gladman DD, Su J, Urowitz MB. More Consistent Antimalarial Intake in First 5 Years of Disease is Associated with Better Prognosis in Patients with Systemic Lupus Erythematous. J Rheumatol. 2018;45(1):90-94. DOI: 10.3899/jrheum.170645Sisó A, Ramos-Casals M, Bové A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus. 2008;17(4):281-288. DOI: 10.1177/0961203307086503Sisó A, Ramos-Casals M, Bové A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus. 2008;17(4):281-288. DOI: 10.1177/0961203307086503Pons-Estel GJ, Alarcón GS, McGwin G Jr et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830-839. DOI: 10.1002/art.24538Pons-Estel GJ, Alarcón GS, McGwin G Jr et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830-839. DOI: 10.1002/art.24538Zavala-Miranda MF, Perez-Arias AA, Márquez-Macedo SE et al. Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico. Rheumatology. 2023;62(3):1136–1144. DOI: 10.1093/rheumatology/keac407Zavala-Miranda MF, Perez-Arias AA, Márquez-Macedo SE et al. Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico. Rheumatology. 2023;62(3):1136–1144. DOI: 10.1093/rheumatology/keac407Sciascia S, Mompean E, Radin M et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig. 2017;37(6):519-524. DOI: 10.1007/s40261-017-0518-zSciascia S, Mompean E, Radin M et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig. 2017;37(6):519-524. DOI: 10.1007/s40261-017-0518-zBharati J, Rathi M. Comparison of two steroid regimen. Indian J Nephrol. 2019.;29(5):373-375. DOI: 10.4103/ijn.IJN_299_18Bharati J, Rathi M. Comparison of two steroid regimen. Indian J Nephrol. 2019.;29(5):373-375. DOI: 10.4103/ijn.IJN_299_18Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis. 2022;25(2):121-130. DOI: 10.1111/1756-185X.14265Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis. 2022;25(2):121-130. DOI: 10.1111/1756-185X.14265Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res. 2018;70(4):582-591. DOI: 10.1002/acr.23322Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res. 2018;70(4):582-591. DOI: 10.1002/acr.23322Singh JA, Hossain A, Kotb A et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137-149. DOI: 10.1186/s12916-016-0673-8Singh JA, Hossain A, Kotb A et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137-149. DOI: 10.1186/s12916-016-0673-8Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-832. DOI: 10.1016/j.autrev.2017.05.017Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-832. DOI: 10.1016/j.autrev.2017.05.017Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028-2035. DOI: 10.1681/ASN.2010050472Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028-2035. DOI: 10.1681/ASN.2010050472Hu W, Chen Y, Wang S et al. Clinical–Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. DOI: 10.2215/CJN.06720615Hu W, Chen Y, Wang S et al. Clinical–Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. DOI: 10.2215/CJN.06720615Hu WX, Chen YH, Bao H et al. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus. 2015;24(10):1067-1075. DOI: 10.1177/0961203315578766Hu WX, Chen YH, Bao H et al. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus. 2015;24(10):1067-1075. DOI: 10.1177/0961203315578766Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018;44(4):561-569. DOI: 10.1016/j.rdc.2018.06.003Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018;44(4):561-569. DOI: 10.1016/j.rdc.2018.06.003Wang Y, Yu F, Song D et al. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford). 2014;53(7):1235-1244. DOI: 10.1093/rheumatology/ket491Wang Y, Yu F, Song D et al. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford). 2014;53(7):1235-1244. DOI: 10.1093/rheumatology/ket491Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483-495. DOI: 10.1038/nrneph.2017.85Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483-495. DOI: 10.1038/nrneph.2017.85Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. DOI: 10.1002/art.10461Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. DOI: 10.1002/art.10461Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-64. DOI: 10.1136/ard.2008.102533Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-64. DOI: 10.1136/ard.2008.102533Rijnink EC, Teng YKO, Wilhelmus S et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. DOI: 10.2215/CJN.10601016Rijnink EC, Teng YKO, Wilhelmus S et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. DOI: 10.2215/CJN.10601016Henderson LK, Masson P, Craig JC et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74-87. DOI: 10.1053/j.ajkd.2012.08.041Henderson LK, Masson P, Craig JC et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74-87. DOI: 10.1053/j.ajkd.2012.08.041Tunnicliffe DJ, Palmer SC, Henderson L et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6(6):CD002922. DOI: 10.1002/14651858.CD002922.pub4Tunnicliffe DJ, Palmer SC, Henderson L et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6(6):CD002922. DOI: 10.1002/14651858.CD002922.pub4Furie R, Rovin BH, Houssiau F et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128. DOI: 10.1056/NEJMoa2001180Furie R, Rovin BH, Houssiau F et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128. DOI: 10.1056/NEJMoa2001180Collins CE, Cortes-Hernandez J, Garcia MA et al. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther. 2020;7(4):949-965. DOI: 10.1007/s40744-020-00243-2Collins CE, Cortes-Hernandez J, Garcia MA et al. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther. 2020;7(4):949-965. DOI: 10.1007/s40744-020-00243-2Furie R, Rovin BH, Houssiau F et al. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022;17(11):1620-1630. DOI: 10.2215/CJN.02520322Furie R, Rovin BH, Houssiau F et al. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022;17(11):1620-1630. DOI: 10.2215/CJN.02520322Rovin BH, Furie R, Teng YKO et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. DOI: 10.1016/j.kint.2021.08.027Rovin BH, Furie R, Teng YKO et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. DOI: 10.1016/j.kint.2021.08.027Frangou E, Bruchfeld A, Fernandez-Juarez GM et al. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective. Nephrol Dial Transplant. 2024;39(5):727-730. DOI: 10.1093/ndt/gfad230Frangou E, Bruchfeld A, Fernandez-Juarez GM et al. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective. Nephrol Dial Transplant. 2024;39(5):727-730. DOI: 10.1093/ndt/gfad230Appel GB, Contreras G, Dooley M.A et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1012. DOI: 10.1681/ASN.2008101028Appel GB, Contreras G, Dooley M.A et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1012. DOI: 10.1681/ASN.2008101028Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-715. Doi: 10.1053/j.ajkd.2012.11.042Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-715. Doi: 10.1053/j.ajkd.2012.11.042Zavada J, Pešickova SS, Ryšava R et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study. Lupus. 2010;19(11):1281-1289. DOI: 10.1177/0961203310371155Zavada J, Pešickova SS, Ryšava R et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study. Lupus. 2010;19(11):1281-1289. DOI: 10.1177/0961203310371155Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018;21(1):200-207. DOI: 10.1111/1756-185X.13152Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018;21(1):200-207. DOI: 10.1111/1756-185X.13152Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6):606-615. DOI: 10.1007/s10165-009-0218-5Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6):606-615. DOI: 10.1007/s10165-009-0218-5Uchino A, Tsukamoto H, Nakashima H et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.Uchino A, Tsukamoto H, Nakashima H et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.Chen W, Tang X, Liu Q et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-244. DOI: 10.1053/j.ajkd.2010.08.036Chen W, Tang X, Liu Q et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-244. DOI: 10.1053/j.ajkd.2010.08.036Lee YH, Lee HS, Choi SJ et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-640. DOI: 10.1177/0961203310389486Lee YH, Lee HS, Choi SJ et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-640. DOI: 10.1177/0961203310389486Deng J, Huo D, Wu Q et al. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med. 2012;227(4):281-288. Doi: 10.1620/tjem.227.281Deng J, Huo D, Wu Q et al. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med. 2012;227(4):281-288. Doi: 10.1620/tjem.227.281Ikeuchi H, Hiromura K, Takahashi S et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24(4):618-625. DOI: 10.3109/14397595.2013.844397Ikeuchi H, Hiromura K, Takahashi S et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24(4):618-625. DOI: 10.3109/14397595.2013.844397Mok CC, To CH, Yu KL et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22(11):1135-1141. DOI: 10.1177/0961203313502864Mok CC, To CH, Yu KL et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22(11):1135-1141. DOI: 10.1177/0961203313502864Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. DOI: 10.7326/M14-1030Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. DOI: 10.7326/M14-1030Melander C, Sallée M, Trolliet P. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579-587. Doi: 10.2215/CJN.04030808Melander C, Sallée M, Trolliet P. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579-587. Doi: 10.2215/CJN.04030808Ramos-Casals M, Soto M.J, Cuadrado MJ et al. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767-776. DOI: 10.1177/0961203309106174Ramos-Casals M, Soto M.J, Cuadrado MJ et al. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767-776. DOI: 10.1177/0961203309106174Díaz-Lagares C, Croca S, Sangle S et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-364. DOI: 10.1016/j.autrev.2011.10.009Díaz-Lagares C, Croca S, Sangle S et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-364. DOI: 10.1016/j.autrev.2011.10.009Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;6494):1215-1226. DOI: 10.1002/art.34359Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;6494):1215-1226. DOI: 10.1002/art.34359Moroni G, Raffiotta F, Trezzi B et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014;53(9):1570-1577. DOI: 10.1093/rheumatology/ket462Moroni G, Raffiotta F, Trezzi B et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014;53(9):1570-1577. DOI: 10.1093/rheumatology/ket462Zickert A, Sundelin B, Svenungsson E et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1(1):e000018. DOI: 10.1136/lupus-2014-000018.Zickert A, Sundelin B, Svenungsson E et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1(1):e000018. DOI: 10.1136/lupus-2014-000018.Galbraith L, Manns B, Hemmelgarn B et al. The steroids in the maintenance of remission of proliferative lupus nephritis (SIMPL) pilot trial. Can J Kidney Health Dis. 2014;1:30. Doi: 10.1186/s40697-014-0030-9Galbraith L, Manns B, Hemmelgarn B et al. The steroids in the maintenance of remission of proliferative lupus nephritis (SIMPL) pilot trial. Can J Kidney Health Dis. 2014;1:30. Doi: 10.1186/s40697-014-0030-9Nossent NC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology. 2000;39(9):969-974. DOI: 10.1093/rheumatology/39.9.969Nossent NC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology. 2000;39(9):969-974. DOI: 10.1093/rheumatology/39.9.969Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-2089. DOI: 10.1136/ard.2010.131995Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-2089. DOI: 10.1136/ard.2010.131995Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. DOI: 10.1056/NEJMoa1014460Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. DOI: 10.1056/NEJMoa1014460Feng L Deng J., Huo DM et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013;18(2):104-110. DOI: 10.1111/nep.12006Feng L Deng J., Huo DM et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013;18(2):104-110. DOI: 10.1111/nep.12006Deng J, Xie H, Zhu, et al. Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis. Clin Nephrol. 2019;91(3):172-179. Doi: 10.5414/CN109450Deng J, Xie H, Zhu, et al. Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis. Clin Nephrol. 2019;91(3):172-179. Doi: 10.5414/CN109450Tamirou F, D'Cruz D, Sangle S et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526-531. DOI: 10.1136/annrheumdis-2014-206897Tamirou F, D'Cruz D, Sangle S et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526-531. DOI: 10.1136/annrheumdis-2014-206897Argolini LM, Frontini G, Elefante E et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. J. Nephrol. 2021;34(2):389-398. DOI: 10.1007/s40620-020-00753-wArgolini LM, Frontini G, Elefante E et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. J. Nephrol. 2021;34(2):389-398. DOI: 10.1007/s40620-020-00753-wChen W, Liu Q, Chen W et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 2012;21(9):944-952. DOI: 10.1177/0961203312442259Chen W, Liu Q, Chen W et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 2012;21(9):944-952. DOI: 10.1177/0961203312442259Zhang H, Liu Z, Zhou M et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28(12):3671-3678. DOI: 10.1681/ASN.2017030263Zhang H, Liu Z, Zhou M et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28(12):3671-3678. DOI: 10.1681/ASN.2017030263Roccatello D, Sciascia S, Baldovino S et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123-1130. DOI: 10.1016/j.autrev.2015.07.017Roccatello D, Sciascia S, Baldovino S et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123-1130. DOI: 10.1016/j.autrev.2015.07.017Moroni G, Longhi S, Giglio E et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31(Suppl 78):75-81.Moroni G, Longhi S, Giglio E et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31(Suppl 78):75-81.Frangou E, Anders H-J, Bajema IM et al. Immunosuppression Withdrawal in Patients with Lupus Nephritis. J Am Soc Nephrol. 2024;35(7):955-958. DOI: 10.1681/ASN.0000000000000365Frangou E, Anders H-J, Bajema IM et al. Immunosuppression Withdrawal in Patients with Lupus Nephritis. J Am Soc Nephrol. 2024;35(7):955-958. DOI: 10.1681/ASN.0000000000000365Malvar A, Pirruccio P, Alberton V et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32(8):1338-1344. DOI: 10.1093/ndt/gfv296Malvar A, Pirruccio P, Alberton V et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32(8):1338-1344. DOI: 10.1093/ndt/gfv296Alvarado AS, Malvar A, Lococo B et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus. 2014;23(8):840-847. DOI: 10.1177/0961203313518625Alvarado AS, Malvar A, Lococo B et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus. 2014;23(8):840-847. DOI: 10.1177/0961203313518625Tang K-T, Tseng C-H, Hsieh T-Y et al. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. Int J Rheum Dis. 2018;21(6):1163-1172. DOI: 10.1111/1756-185X.13321Tang K-T, Tseng C-H, Hsieh T-Y et al. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. Int J Rheum Dis. 2018;21(6):1163-1172. DOI: 10.1111/1756-185X.13321Austin HA, Illei GG, Braun M., Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 2009;20(4):901-911. Doi: 10.1681/ASN.2008060665Austin HA, Illei GG, Braun M., Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 2009;20(4):901-911. Doi: 10.1681/ASN.2008060665Mok C, Ying K, Yim C et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18(12):1091-1095. DOI: 10.1177/0961203309106602Mok C, Ying K, Yim C et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18(12):1091-1095. DOI: 10.1177/0961203309106602Szeto C-C, Kwan BC-H, Lai FM-M et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. 2008;47(11): 1678-1681. Doi: 10.1093/rheumatology/ken335Szeto C-C, Kwan BC-H, Lai FM-M et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. 2008;47(11): 1678-1681. Doi: 10.1093/rheumatology/ken335Chen W, Tang X, Liu Q et al. Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial. Am J Kidney Dis. 2011;57(2):235-244. Doi: 10.1053/j.ajkd.2010.08.036Chen W, Tang X, Liu Q et al. Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial. Am J Kidney Dis. 2011;57(2):235-244. Doi: 10.1053/j.ajkd.2010.08.036Radhakrishnan J, Moutzouris D-A, Ginzler E.M et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152-160. DOI: 10.1038/ki.2009.412Radhakrishnan J, Moutzouris D-A, Ginzler E.M et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152-160. DOI: 10.1038/ki.2009.412Yap DY, Yu X, Chen XM et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17(4):352-357. DOI: 10.1111/j.1440-1797.2012.01574.xYap DY, Yu X, Chen XM et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17(4):352-357. DOI: 10.1111/j.1440-1797.2012.01574.xChavarot N, Verhelst D, Pardon A et al. Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. Doi: 10.1097/MD.0000000000007429Chavarot N, Verhelst D, Pardon A et al. Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. Doi: 10.1097/MD.0000000000007429Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: Assessing the evidence. Nephrol Dial Transplant. 2009;24(1):15-20. DOI: 10.1093/ndt/gfn565Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: Assessing the evidence. Nephrol Dial Transplant. 2009;24(1):15-20. DOI: 10.1093/ndt/gfn565Mosca M, Bencivelli W, Neri R et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61(4):1502-1509. DOI: 10.1046/j.1523-1755.2002.00280.xMosca M, Bencivelli W, Neri R et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61(4):1502-1509. DOI: 10.1046/j.1523-1755.2002.00280.xIoannidis JPA, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57(1):258-264. DOI: 10.1046/j.1523-1755.2000.00832.xIoannidis JPA, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57(1):258-264. DOI: 10.1046/j.1523-1755.2000.00832.xRivera F, Mérida E, Illescas ML et al. Mycophenolate in Refractory and Relapsing Lupus Nephritis. Am J Nephrol. 2014;40(2):105-112. DOI: 10.1159/000365256Rivera F, Mérida E, Illescas ML et al. Mycophenolate in Refractory and Relapsing Lupus Nephritis. Am J Nephrol. 2014;40(2):105-112. DOI: 10.1159/000365256Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9-21. DOI: 10.1002/art.25061Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9-21. DOI: 10.1002/art.25061Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-678. DOI: 10.1191/0961203304lu2012oaKatsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-678. DOI: 10.1191/0961203304lu2012oaDe Rosa M, Azzato F, Toblli JE et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788-794. DOI: 10.1016/j.kint.2018.05.021De Rosa M, Azzato F, Toblli JE et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788-794. DOI: 10.1016/j.kint.2018.05.021Arriens C, Chen S, Karp DR et al. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017;185:3-9. DOI: 10.1016/j.clim.2016.11.019Arriens C, Chen S, Karp DR et al. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017;185:3-9. DOI: 10.1016/j.clim.2016.11.019Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res. 2000;13(6):406-408. DOI: 10.1002/1529-0131(200012)13:6<406::AID-ART11>3.0.CO;2-2Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res. 2000;13(6):406-408. DOI: 10.1002/1529-0131(200012)13:6<406::AID-ART11>3.0.CO;2-2Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheum. 2013;27(3):329-340. DOI: 10.1016/j.berh.2013.07.001Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheum. 2013;27(3):329-340. DOI: 10.1016/j.berh.2013.07.001Fei Y, Wu Q, Zhang W et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol. 2013;31(1):62-68.Fei Y, Wu Q, Zhang W et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol. 2013;31(1):62-68.Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19(2):162-169. DOI: 10.1177/0961203309350320Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19(2):162-169. DOI: 10.1177/0961203309350320Jesus D, Rodrigues M, da Silva JAP, Inês L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27(8):1358-1362. DOI: 10.1177/0961203318758508Jesus D, Rodrigues M, da Silva JAP, Inês L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27(8):1358-1362. DOI: 10.1177/0961203318758508Tanaka Y, Takeuchi T, Miyasaka N et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatol. 2016;26(1):80-86. DOI: 10.3109/14397595.2015.1060665Tanaka Y, Takeuchi T, Miyasaka N et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatol. 2016;26(1):80-86. DOI: 10.3109/14397595.2015.1060665Weidenbusch M, Römmele C, Schröttle A, Anders H-J. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106-111. Doi: 10.1093/ndt/gfs285Weidenbusch M, Römmele C, Schröttle A, Anders H-J. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106-111. Doi: 10.1093/ndt/gfs285Alshaiki F, Obaid E, Almuallim A et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018.;5(2):118-126. DOI: 10.5152/eurjrheum.2018.17096Alshaiki F, Obaid E, Almuallim A et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018.;5(2):118-126. DOI: 10.5152/eurjrheum.2018.17096Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. DOI: 10.1016/j.kint.2020.11.003Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. DOI: 10.1016/j.kint.2020.11.003Duran-Barragan S, McGwin G Jr, Vila LM et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus – results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093-1096. DOI: 10.1093/rheumatology/ken208Duran-Barragan S, McGwin G Jr, Vila LM et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus – results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093-1096. DOI: 10.1093/rheumatology/ken208Kanda H, Kubo K, Tateishi S et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus. 2005;14(4):288-292. DOI: 10.1191/0961203305lu2076oaKanda H, Kubo K, Tateishi S et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus. 2005;14(4):288-292. DOI: 10.1191/0961203305lu2076oaTse KC, Li FK, Tang S et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus. 2005;14(12):947-952. DOI: 10.1191/0961203305lu2249oaTse KC, Li FK, Tang S et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus. 2005;14(12):947-952. DOI: 10.1191/0961203305lu2249oaMorales E, Galindo M. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. 2022;81(9):1337-1338. Doi: 10.1136/annrheumdis-2022-222512Morales E, Galindo M. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. 2022;81(9):1337-1338. Doi: 10.1136/annrheumdis-2022-222512Onuora S. SGLT2 inhibitors protect podocytes in lupus nephritis. Nat Rev Rheumatol. 2023;19(10):605. DOI: 10.1038/s41584-023-01024-1Onuora S. SGLT2 inhibitors protect podocytes in lupus nephritis. Nat Rev Rheumatol. 2023;19(10):605. DOI: 10.1038/s41584-023-01024-1Zhao XY, Li SS, He YX et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023;82(10):1328-1340. DOI: 10.1136/ard-2023-224242Zhao XY, Li SS, He YX et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023;82(10):1328-1340. DOI: 10.1136/ard-2023-224242Furer V, Rondaan C, Heijstek M.W et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020.;79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882Furer V, Rondaan C, Heijstek M.W et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020.;79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882Chang YS, Liu CJ, Wu TH et al. Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: A nationwide population-based study in Taiwan. Rheumatology (Oxford). 2013;52(1):166-172. DOI: 10.1093/rheumatology/kes325Chang YS, Liu CJ, Wu TH et al. Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: A nationwide population-based study in Taiwan. Rheumatology (Oxford). 2013;52(1):166-172. DOI: 10.1093/rheumatology/kes325Devlin A, Waikar SS, Solomon DH et al. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken). 2011;63(12):1642-1653. DOI: 10.1002/acr.20607Devlin A, Waikar SS, Solomon DH et al. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken). 2011;63(12):1642-1653. DOI: 10.1002/acr.20607Weng CH, Hsu CW, Yu CC et al. Peritoneal dialysis and haemodialysis in systemic lupus erythematosus patients: Comparison of clinical outcomes. Kidney Blood Press Res. 2009;32(6):451-456. DOI: 10.1159/000266480Weng CH, Hsu CW, Yu CC et al. Peritoneal dialysis and haemodialysis in systemic lupus erythematosus patients: Comparison of clinical outcomes. Kidney Blood Press Res. 2009;32(6):451-456. DOI: 10.1159/000266480Contreras G, Pagan J, Chokshi R et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. Clin J Am Soc Nephrol. 2014;9(11):1949-1956. DOI: 10.2215/CJN.02500314Contreras G, Pagan J, Chokshi R et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. Clin J Am Soc Nephrol. 2014;9(11):1949-1956. DOI: 10.2215/CJN.02500314Levy B, Couchoud C, Rougier J-P et al. Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002–2012. Lupus. 2015;24(10):1111-1121. DOI:10.1177/0961203315578763Levy B, Couchoud C, Rougier J-P et al. Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002–2012. Lupus. 2015;24(10):1111-1121. DOI:10.1177/0961203315578763Bataille S, Burtey S, Decourt A et al. Antiphospholipid antibodies and hemodialysis: a frequent association linked to arteriovenous fistula thrombosis. Nephrol Ther. 2015;11(1):27-33. DOI: 10.1016/j.nephro.2014.08.005Bataille S, Burtey S, Decourt A et al. Antiphospholipid antibodies and hemodialysis: a frequent association linked to arteriovenous fistula thrombosis. Nephrol Ther. 2015;11(1):27-33. DOI: 10.1016/j.nephro.2014.08.005Park ES, Ahn SS, Jung SM et al. Renal outcome after kidney-transplantation in Korean patients with lupus nephritis. Lupus. 2018;27(3):461-467. DOI:10.1177/0961203317725591Park ES, Ahn SS, Jung SM et al. Renal outcome after kidney-transplantation in Korean patients with lupus nephritis. Lupus. 2018;27(3):461-467. DOI:10.1177/0961203317725591Jorge A, Wallace ZS, Lu N et al. Renal transplantation and survival among patients with lupus nephritis: a cohort study. Ann Intern Med. 2019;170(4):240-247. DOI: 10.7326/M18-1570Jorge A, Wallace ZS, Lu N et al. Renal transplantation and survival among patients with lupus nephritis: a cohort study. Ann Intern Med. 2019;170(4):240-247. DOI: 10.7326/M18-1570Chung MC, Yu TM, Shu KH et al. Influence of pretransplantation dialysis time and lupus activity on outcome of kidney transplantation in systemic lupus erythematosus. Transplant Proc. 2014;46(2):336-338. DOI: 10.1016/j.transproceed.2013.11.085Chung MC, Yu TM, Shu KH et al. Influence of pretransplantation dialysis time and lupus activity on outcome of kidney transplantation in systemic lupus erythematosus. Transplant Proc. 2014;46(2):336-338. DOI: 10.1016/j.transproceed.2013.11.085Contreras G, Mattiazzi A, Guerra G et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol. 2010;219(7):1200-1207. DOI: 10.1681/ASN.2009101093Contreras G, Mattiazzi A, Guerra G et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol. 2010;219(7):1200-1207. DOI: 10.1681/ASN.2009101093Morales JM, Serrano M, Martinez-Flores JA et al. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation. 2019;103(3):481-486. DOI: 10.1097/TP.0000000000002510Morales JM, Serrano M, Martinez-Flores JA et al. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation. 2019;103(3):481-486. DOI: 10.1097/TP.0000000000002510Wagenknecht DR, Fastenau DR, Torry RJ et al. Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies. Transpl Int. 2000;(suppl 1):S78–S81. DOI: 10.1007/s001470050280Wagenknecht DR, Fastenau DR, Torry RJ et al. Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies. Transpl Int. 2000;(suppl 1):S78–S81. DOI: 10.1007/s001470050280Song D, Wu LH, Wang FM et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):12. DOI: 10.1186/ar4142Song D, Wu LH, Wang FM et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):12. DOI: 10.1186/ar4142Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213Arnaud L, Mathian A, Ruffatti A et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;1393):281-291. DOI: 10.1016/j.autrev.2013.10.014Arnaud L, Mathian A, Ruffatti A et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;1393):281-291. DOI: 10.1016/j.autrev.2013.10.014Arnaud L, Mathian A, Devilliers H et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192-200. DOI: 10.1016/j.autrev.2014.10.019Arnaud L, Mathian A, Devilliers H et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192-200. DOI: 10.1016/j.autrev.2014.10.019Tarr T, Lakos G, Bhattoa HP et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16(1):39-45. DOI: 10.1177/0961203306074767Tarr T, Lakos G, Bhattoa HP et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16(1):39-45. DOI: 10.1177/0961203306074767Tektonidou MG, Laskari K, Panagiotakos DB et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61(1):29-36. Doi: 10.1002/art.24232Tektonidou MG, Laskari K, Panagiotakos DB et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61(1):29-36. Doi: 10.1002/art.24232Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. doi: 10.1111/j.1538-7836.2009.03674.xPengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. doi: 10.1111/j.1538-7836.2009.03674.xPengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018. 132(13):13651371. doi: 10.1182/blood-2018-04-848333Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018. 132(13):13651371. doi: 10.1182/blood-2018-04-848333Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016. 15(1):38-49. DOI: 10.1016/j.autrev.2015.08.010Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016. 15(1):38-49. DOI: 10.1016/j.autrev.2015.08.010Legault K, Schunemann H, Hillis C et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018;16(8):1656-1664. Doi: 10.1111/jth.14192Legault K, Schunemann H, Hillis C et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018;16(8):1656-1664. Doi: 10.1111/jth.14192Delate T, Hansen ML, Gutierrez AC, Le KN. Indications for Rituximab Use in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2020;26(7):832-838. DOI: 10.18553/jmcp.2020.26.7.832Delate T, Hansen ML, Gutierrez AC, Le KN. Indications for Rituximab Use in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2020;26(7):832-838. DOI: 10.18553/jmcp.2020.26.7.832Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-2094. DOI: 10.1182/bloodadvances.2018019596Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-2094. DOI: 10.1182/bloodadvances.2018019596Sciascia S, Radin M, Yazdany J et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. Doi: 10.1007/s00296-017-3686-5Sciascia S, Radin M, Yazdany J et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. Doi: 10.1007/s00296-017-3686-5Kello N, Khoury LE, Marder G et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. Doi: 10.1016/j.semarthrit.2018.11.005Kello N, Khoury LE, Marder G et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. Doi: 10.1016/j.semarthrit.2018.11.005Imbasciati E, Tincani A, Gregorini G et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2009;24(2):519-525. DOI: 10.1093/ndt/gfn348Imbasciati E, Tincani A, Gregorini G et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2009;24(2):519-525. DOI: 10.1093/ndt/gfn348Buyon JP, Kim MY, Guerra MM et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153-163. DOI: 10.7326/M14-2235Buyon JP, Kim MY, Guerra MM et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153-163. DOI: 10.7326/M14-2235Tani C, Zucchi D, Haase I et al. Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? a multicentre study. Rheumatology (Oxford). 2021;60(12):5610-5619. DOI: 10.1093/rheumatology/keab155Tani C, Zucchi D, Haase I et al. Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? a multicentre study. Rheumatology (Oxford). 2021;60(12):5610-5619. DOI: 10.1093/rheumatology/keab155Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. DOI: 10.1136/annrheumdis-2016-209770Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. DOI: 10.1136/annrheumdis-2016-209770Fakhouri F, Schwotzer N, Cabiddu G et al. Glomerular diseases in pregnancy: Pragmatic recommendations for clinical management. Kidney Int. 2023;103(2):264-281. DOI: 10.1016/j.kint.2022.10.029Fakhouri F, Schwotzer N, Cabiddu G et al. Glomerular diseases in pregnancy: Pragmatic recommendations for clinical management. Kidney Int. 2023;103(2):264-281. DOI: 10.1016/j.kint.2022.10.029Hoeltzenbein M, Tissen-Diabate T, Fietz AK et al. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors – treatment or hypertension related? an observational cohort study. Pregnancy Hypertens. 2018;13:65-71. DOI: 10.1016/j.preghy.2018.04.022Hoeltzenbein M, Tissen-Diabate T, Fietz AK et al. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors – treatment or hypertension related? an observational cohort study. Pregnancy Hypertens. 2018;13:65-71. DOI: 10.1016/j.preghy.2018.04.022Weber-Schoendorfer C, Kayser A, Tissen-Diabate T et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141. DOI: 10.1097/HJH.0000000000002233Weber-Schoendorfer C, Kayser A, Tissen-Diabate T et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141. DOI: 10.1097/HJH.0000000000002233Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;32493):150-154. DOI: 10.1056/NEJM199101173240303Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;32493):150-154. DOI: 10.1056/NEJM199101173240303Levy RA, Vilela VS, Cataldo MJ et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;1096):401-404. DOI: 10.1191/096120301678646137Levy RA, Vilela VS, Cataldo MJ et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;1096):401-404. DOI: 10.1191/096120301678646137Clowse ME, Magder L, Witter F et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640-3647. DOI: 10.1002/art.22159Clowse ME, Magder L, Witter F et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640-3647. DOI: 10.1002/art.22159Koh JH, Ko HS, Kwok SK et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24(2):210-217. DOI: 10.1177/0961203314555352Koh JH, Ko HS, Kwok SK et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24(2):210-217. DOI: 10.1177/0961203314555352Leroux M, Desveaux C, Parcevaux M et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus. 2015;24(13):1384-1391. DOI:10.1177/0961203315591027Leroux M, Desveaux C, Parcevaux M et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus. 2015;24(13):1384-1391. DOI:10.1177/0961203315591027Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(5):835-848. DOI: 10.1111/bcp.12872.Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(5):835-848. DOI: 10.1111/bcp.12872.Bramham K, Hunt BJ, Bewley S et al. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol. 2011;38(9):1906-1913. DOI: 10.3899/jrheum.100997Bramham K, Hunt BJ, Bewley S et al. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol. 2011;38(9):1906-1913. DOI: 10.3899/jrheum.100997Roberge S, Villa P, Nicolaides K et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141146. DOI: 10.1159/000336662Roberge S, Villa P, Nicolaides K et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141146. DOI: 10.1159/000336662Xu TT, Zhou F, Deng CY et al. Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. J Clin Hypertens (Greenwich). 2015;17(7):567-573. DOI: 10.1111/jch.12541Xu TT, Zhou F, Deng CY et al. Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. J Clin Hypertens (Greenwich). 2015;17(7):567-573. DOI: 10.1111/jch.12541Davidson KW, Barry MJ, Mangione CM et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. Journ Am Med Assoc. 2021;326(12):1186-1191. DOI: 10.1001/jama.2021.14781Davidson KW, Barry MJ, Mangione CM et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. Journ Am Med Assoc. 2021;326(12):1186-1191. DOI: 10.1001/jama.2021.14781Eudy AM, Siega-Riz AM, Engel SM et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77(6):855-860. DOI: 10.1136/annrheumdis-2017-212535Eudy AM, Siega-Riz AM, Engel SM et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77(6):855-860. DOI: 10.1136/annrheumdis-2017-212535Lightstone L, Hladunewich MA. Lupus nephritis and pregnancy: concerns and management. Semin Nephrol. 2017;3794):347-353. DOI: 10.1016/j.semnephrol.2017.05.006Lightstone L, Hladunewich MA. Lupus nephritis and pregnancy: concerns and management. Semin Nephrol. 2017;3794):347-353. DOI: 10.1016/j.semnephrol.2017.05.006Gleeson S, Lightstone L. Glomerular disease and pregnancy. Adv Chronic Kidney Dis. 2020;2796):469-476. DOI: 10.1053/j.ackd.2020.08.001Gleeson S, Lightstone L. Glomerular disease and pregnancy. Adv Chronic Kidney Dis. 2020;2796):469-476. DOI: 10.1053/j.ackd.2020.08.001Webster P, Wardle A, Bramham K et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23(11):1192-1196. DOI: 10.1177/0961203314540353Webster P, Wardle A, Bramham K et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23(11):1192-1196. DOI: 10.1177/0961203314540353Russell MD, Dey M, Flint J et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62(4):48-88. DOI: 10.1093/rheumatology/keac551Russell MD, Dey M, Flint J et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62(4):48-88. DOI: 10.1093/rheumatology/keac551Fischer-Betz R, Specker C, Brinks R et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52(6):1070-1076. DOI: 10.1093/rheumatology/kes425Fischer-Betz R, Specker C, Brinks R et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52(6):1070-1076. DOI: 10.1093/rheumatology/kes425de Jesús GR, Rodrigues G, de Jesús NR et al. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16(2):403. DOI: 10.1007/s11926-013-0403-6de Jesús GR, Rodrigues G, de Jesús NR et al. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16(2):403. DOI: 10.1007/s11926-013-0403-6Mak A, Cheung MW, Cheak AA et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford). 2010;49(2):281-288. DOI: 10.1093/rheumatology/kep373Mak A, Cheung MW, Cheak AA et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford). 2010;49(2):281-288. DOI: 10.1093/rheumatology/kep373Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115(6):1256-1262. DOI: 10.1097/AOG.0b013e3181deba40Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115(6):1256-1262. DOI: 10.1097/AOG.0b013e3181deba40Larosa M, Le Guern V, Guettrot-Imbert G et al. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in lupus women: the French GR2 study. Rheumatology (Oxford). 2022;61(9):3657-3666. DOI: 10.1093/rheumatology/keab943Larosa M, Le Guern V, Guettrot-Imbert G et al. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in lupus women: the French GR2 study. Rheumatology (Oxford). 2022;61(9):3657-3666. DOI: 10.1093/rheumatology/keab943Moroni G, Radice A, Giammarresi G et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009;68(2):234-237. DOI: 10.1136/ard.2008.094508Moroni G, Radice A, Giammarresi G et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009;68(2):234-237. DOI: 10.1136/ard.2008.094508Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-1274. DOI: 10.1136/ard.2009.117200Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-1274. DOI: 10.1136/ard.2009.117200Системная красная волчанка. Рациональная фармакотерапия ревматических заболеваний. Под ред. В.А. Насоновой, Е.Л. Насонова. Издательство «Литтерра». 2003.С.169-180.Systamnaya krasnaya volchanka. Ratsionalnaya farmakoterapia revmaticheskikh zabolevanyj. Ed by V.A. Nasonova, E.L. Nasonov. Publisher “Litterra” 2003.P.169-180 (In Russian)Соловьев СК, Асеева ЕА, Попкова ТВ и соавт. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14.Solovjov SK, Aseeva EA, Popkova TV et al. Systamnaya krasnaya volchanka: novie gorizonty diagnostiki y terapii. Nauchno-praktichskaya revmatologia. 2020;58(1):5-14. (In Russian)

The authors declare that there are no conflicts of interest present.